Potential advance in HER+ patients with combination therapy
Results from the monarcHER and KATE2 trials presented
PARP inhibitors expand their role beyond BRCA mutations in first-line, newly diagnosed ovarian cancer
Favourable results were presented from three phase III trials which are likely to lead to a practice-changing role for PARP inhibitors in the treatment of newly diagnosed advanced ovarian cancer
Anlotinib improves overall survival in relapsed SCLC
Results of ALTER 1202 reveal survival benefit for anlotinib third-line in small-cell lung cancer
Cediranib–olaparib combination is effective regardless of disease mutations
Results from the BAROCCO trial may help define the optimum treatment schedule for an antiangiogenic–PARP inhibitor combination in recurrent, platinum-resistant ovarian cancer
Not just for girls, so who else should be vaccinated for HPV?
Extending an HPV vaccination programme to include boys aged 12–14 years could help reduce the incidence of these infections
A potential new targeted treatment for Notch mutation-positive tumours
A growing body of evidence has identified Notch mutations as a potential target in adenoid cystic carcinoma (ACC), a rare type of salivary gland carcinoma
Is tissue tumour mutational burden a predictive biomarker for immunotherapy in lung cancer?
Two post-hoc analyses of KEYNOTE studies presented at ESMO 2019
Precision medicine bursts onto the biliary tract cancer scene
The management of biliary tract cancers, especially cholangiocarcinoma, is rapidly changing with emerging new precision medicine strategies
Oncologists can have a pivotal role in health policy
Effective NCCPs should help medical oncologists to provide better cancer care, but they cannot work in isolation